Phase 1 study of intraventricular ¹³¹I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.

ABSTRACT:

Background

The prognosis for metastatic and recurrent tumors of the central nervous system (CNS) remains dismal, and the need for newer therapeutic targets and modalities is critical. The cell surface glycoprotein B7H3 is expressed on a range of solid tumors with a restricted expression on normal tissues. We hypothesized that compartmental radioimmunotherapy (cRIT) with the anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly could safely target CNS malignancies.

Patients and methods

We conducted a phase I trial of intraventricular ¹³¹I-omburtamab using a standard 3 + 3 design. Eligibility criteria included adequate cerebrospinal fluid (CSF) flow, no major organ toxicity, and for patients > dose level 6, availability of autologous stem cells

SUBMITTER: Kramer K 

PROVIDER: S-EPMC9655863 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature